Ships carrying fuel from India's Nayara refinery in limbo, sources say
SINGAPORE (Reuters) -Three vessels laden with oil products from India's Nayara Energy have yet to discharge their cargoes, hindered by new EU sanctions on the Russia-backed refiner, according to shipping data and sources.
Nayara Energy, which runs India's third-biggest refinery, is majority-owned by Russian entities, including oil major Rosneft. It was hit with European Union sanctions on July 18 targeting Russia and its oil trade, causing shippers and traders to shun dealing with its cargoes.
The Panamax-sized tanker Alora, chartered by Nayara Energy and carrying around 60,000 metric tons (472,800 barrels) of jet fuel loaded in early June, has been anchored off Portugal's Sines port since arriving there on July 18, Kpler and LSEG data showed.
The cargo has been paid for, said a person familiar with the matter. However, the vessel has been unable to discharge as some EU oil surveyors and other companies are reluctant to deal with products linked to a sanctioned entity, according to the person and a second source.
Reuters was not able to learn the identity of the buyer.
Sources for this article were not authorised to speak to media and declined to be identified.
Nayara Energy did not immediately respond to a Reuters request for comment. It typically sells at least 2-3 spot cargoes of diesel and jet fuel per month.
The refiner, which called the sanctions unjustified and illegal, has been forced to reduce operations at its 400,000-barrels-per-day crude unit due to fuel storage constraints. Some vessel owners have also asked to end their contracts, sources have said.
TWO MORE TANKERS
A second Panamax tanker, Em Zenith, had been scheduled to arrive at Malaysia's Tanjung Pelepas port this Thursday, but it reversed course on Tuesday and is anchored in the Straits of Malacca, Kpler and LSEG data showed.
The Singapore-flagged ship is carrying around 40,000 tons of diesel loaded from Nayara Energy's Vadinar port in mid-July, according to the data. The cargo was likely intended to be used for bunker fuel blending, several industry sources said.
Equatorial Marine owns Em Zenith, according to two shipbroking sources. The firm, a major bunker supplier in Singapore, did not immediately reply to a request for comment.
A third tanker, Panamax-sized Pacific Martina, chartered by Shell, has been floating near the Gulf of Oman since last week after receiving 60,000 tons of jet fuel from Vadinar port on July 18. The cargo has yet to find a buyer, said the first source.
Shell declined to comment.
Last week, a crude tanker was diverted away from Nayara Energy's Vadinar port, and two product tankers skipped planned diesel loadings from the refiner.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
US, China extend tariff truce by 90 days, staving off surge in duties
By Trevor Hunnicutt, Andrea Shalal and Joe Cash WASHINGTON/BEIJING (Reuters) -The United States and China have extended a tariff truce for another 90 days, staving off triple-digit duties on each other's goods as U.S. retailers get ready to ramp up inventories ahead of the critical end-of-year holiday season. U.S. President Donald Trump announced on his Truth Social platform on Monday that he had signed an executive order suspending the imposition of higher tariffs until 12:01 a.m. EST (0501 GMT) on November 10, with all other elements of the truce to remain in place. China's Commerce Ministry issued a parallel pause on extra tariffs early on Tuesday, also postponing for 90 days the addition of U.S. firms it had targeted in April to trade and investment restriction lists. "The United States continues to have discussions with the PRC to address the lack of trade reciprocity in our economic relationship and our resulting national and economic security concerns," Trump's executive order stated, using the acronym for the People's Republic of China. The tariff truce between Beijing and Washington had been due to expire on Tuesday at 12:01 a.m. EDT (0401 GMT). The extension until early November buys crucial time for the seasonal autumn surge of imports for the Christmas season, including electronics, apparel and toys at lower tariff rates. The new order prevents U.S. tariffs on Chinese goods from shooting up to 145%, while Chinese tariffs on U.S. goods were set to hit 125% - rates that would have resulted in a virtual trade embargo between the two countries. It locks in place - at least for now - a 30% tariff on Chinese imports, with Chinese duties on U.S. imports at 10%. There was relief on the streets of China's capital, where officials are grappling with the challenge Trump's trade policy poses to the economy's long-standing, export-oriented growth model. "I don't think either China or the United States wants to see their relationship continue to deteriorate," said Wang Mingyue, a 39-year-old professional working in robotics. "That's why both are taking the current approach, but the game and confrontation may not be over yet - so there's still risk." Markets showed optimism for a breakthrough between the two superpowers, with Asian stocks rising and currencies mostly steady, after treading water for weeks. Trump told CNBC last week that the U.S. and China were getting very close to a trade agreement and he would meet Xi before the end of the year if a deal was struck. TRADE 'DETENTE' CONTINUED The two sides announced a truce in their trade dispute in May after talks in Geneva, Switzerland, agreeing to a 90-day period to allow further talks. They met again in Stockholm, Sweden, in late July, and U.S. negotiators returned to Washington with a recommendation that Trump extend the deadline. Treasury Secretary Scott Bessent has said repeatedly that the triple-digit import duties both sides slapped on each other's goods in the spring were untenable and had essentially imposed a trade embargo between the world's two largest economies. "It wouldn't be a Trump-style negotiation if it didn't go right down to the wire," said Kelly Ann Shaw, a senior White House trade official during Trump's first term and now with law firm Akin Gump Strauss Hauer & Feld. She said Trump had likely pressed China for further concessions before agreeing to the extension. Trump pushed for additional concessions on Sunday, urging China to quadruple its soybean purchases, although analysts questioned the feasibility of any such deal. Trump did not repeat the demand on Monday. "What is he going to offer in exchange?" said Xu Tianchen, senior economist at the Economist Intelligence Unit in Beijing. "China says: 'you should allow us to buy more high-tech goods,' but the U.S. is reluctant." Xu said Trump's refusal to ease his 20% tariff on Chinese goods over fentanyl flows suggested both sides believed they could continue to withstand the trade shock. "If (Trump) escalates, he will struggle to gain an upper hand over China, which has many cards to play," Xu said. China's exports to the U.S. fell an annual 21.7% last month, according to the country's latest trade data, while shipments to Southeast Asia rose 16.6% over the same period as manufacturers sought to pivot to new markets and capitalise on a separate reprieve that allowed trans-shipment to the U.S. Separate U.S. data released last week showed the trade deficit with China shrank to its lowest in more than 21 years in June. Still, analysts expect the world's two largest economies to reach an agreement before long, as their deep interdependence makes pursuing alternative markets unattractive over the long term. Ryan Majerus, a former U.S. trade official now with the King & Spalding law firm, said the news would give both sides more time to work through long-standing trade concerns. 'This will undoubtedly lower anxiety on both sides as talks continue, and as the U.S. and China work toward a framework deal in the fall," he said. Washington has also been pressing Beijing to stop buying Russian oil to pressure Moscow over its war in Ukraine, with Trump threatening to impose secondary tariffs on China. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Can Rigetti's Chiplet Strategy Secure Its Spot in DARPA's Next Phase?
Rigetti Computing RGTI is taking an aggressive step to scale its quantum systems with a chiplet-based design — smaller, high-quality modules linked together to overcome the limits of single-chip architectures. The company is targeting the rollout of a 4×9-qubit chiplet system in the near term and aims to exceed 100 qubits with 99.5%–99.7% median two-qubit fidelities by year-end. These milestones align with DARPA's performance criteria as it narrows participants in its Quantum Benchmarking Initiative, a multi-year program to develop utility-scale systems with over 10,000 qubits. Achieving them could secure Rigetti's place in the next phase and open the door to larger government contracts. To support this plan, Rigetti has strengthened its operational base. In February, a $35 million investment from Quanta Computer brings both funding and manufacturing expertise, with Quanta set to produce much of the non-QPU hardware, such as control systems and refrigeration, thus allowing Rigetti to focus on chiplet design and integration. Meanwhile, projects like the AFOSR-backed ABAA fabrication program and Innovate UK partnerships, including a planned 36-qubit upgrade at the NQCC, aim to enhance chip quality and scalability. Key milestones for investors to watch in the remainder of 2025 include the upcoming 4×9 chiplet demonstration, DARPA's Phase B decision, and progress in Quanta's production. Peers Updates International Business Machines IBM has continued to advance its superconducting quantum roadmap, showcasing the 1,121-qubit Condor processor and outlining a path toward modular quantum systems. Alongside hardware gains, IBM is building out a robust quantum cloud platform and software ecosystem to drive developer adoption. The company's near-term focus remains on improving gate fidelities, expanding system access, and preparing the architecture for integration into larger, modular configurations over the next several years. IonQ IONQ is pursuing growth through its trapped-ion technology, which offers high coherence times and precise operations. The company's 2025-end target centers on achieving AQ 64 (algorithmic qubits), a performance metric designed to better reflect real-world utility than raw qubit counts. IonQ is investing in scaling its hardware manufacturing capacity while expanding partnerships in cloud and enterprise markets. The longer-term strategy focuses on increasing algorithmic performance year over year to bridge toward commercially relevant quantum advantage. Rigetti's Price Performance, Valuation and Estimates Shares of RGTI have gained 4.7% in the year-to-date period compared with the industry's growth of 21.7%. Image Source: Zacks Investment Research From a valuation standpoint, Rigetti trades at a price-to-book ratio of 22.41, above the industry average. RGTI carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Rigetti's 2025 earnings implies a significant 86.1% rise from the year-ago period. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report International Business Machines Corporation (IBM) : Free Stock Analysis Report IonQ, Inc. (IONQ) : Free Stock Analysis Report Rigetti Computing, Inc. (RGTI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Truckin' To 2030: Europe's Green Horizon For Medical Cannabis & Hemp
Europe's cannabis sector is undergoing a profound transformation—one driven by evolving regulations, changing social attitudes, and rising institutional investor interest. Germany, as the continent's largest economy, stands at the heart of this transition, leading a dual trajectory in both medical cannabis and industrial hemp. What was once niche is now positioned as a cornerstone of sustainable health, clean materials, and innovative investment opportunities. You might say that the European industry appears to be built to last. Market Overview and Segmentation Europe's cannabis landscape is divided into two distinct segments: THC‑containing cannabis (above 0.3% THC), regulated primarily for medical and sometimes adult-use purposes; and industrial hemp (below 0.3% THC), employed in foods, textiles, bioplastics, cosmetics, and construction. While sharing a botanical origin—Cannabis sativa L.—each operates under its own regulatory framework, supply chain, and market focus. Understanding this segmentation is essential for investors and policymakers evaluating risk and opportunity. Globally, the medical cannabis market was valued at approximately €4.5 billion in 2024 and is projected to reach over €62 billion by 2030—recording a staggering compound annual growth rate (CAGR) of 55%. Europe, fueled by demographic shifts and legal liberalization, is forecasted to be the fastest-growing region. Meanwhile, the industrial hemp market is poised to triple to around €15 billion by 2030, according to UNCTAD projections, driven by surging demand for climate-friendly materials and plant-based nutrition. Regulatory Developments The eyes of the world are on Germany, as it has emerged as the regulatory focal point in Europe. Its Cannabis Act (CanG), enacted in 2024, removed restrictive quotas and significantly expanded medical access. A complementary Medical Cannabis Act (MedCanG) is under development, emphasizing pharmacy-based distribution while tightening telemedicine channels. In parallel, a new Industrial Hemp Liberalization Act is expected in 2026, poised to eliminate outdated restrictions and modernize hemp production regulation. On the EU level, the classification of CBD as a Novel Food is opening doors to wellness and nutrition markets previously inaccessible for hemp producers. Growth in Medical Cannabis Since medical cannabis legalization in 2017, German patient numbers have soared—with 300,000 individuals receiving prescriptions in 2024, estimated to grow to 840,000 in 2025. By 2030, the market is expected to reach €650 million. Innovations in formulation—such as high-purity extracts, dronabinol pills, and cannabinoid pastilles—are expanding therapeutic use across neurology, chronic pain, and oncology. Major operators like SYNBIOTIC SE are leading the charge, developing standardized dosage forms and investing in regulated production. Global companies such as Tilray, Aurora, OrganiGram, and Canada's Sanity Group (via its partnership with OrganiGram) are deepening their European presence, underlining the continent's rising magnetism for international cannabis investors. Industrial Hemp as a Sustainability Engine Industrial hemp, long undervalued, is now recognized as a strategic asset in Europe's green economy. German industrial hemp sales grew from €526 million in 2023 to a projected €3 billion by 2032 (CAGR ~22%). Applications range from hemp-protein powders to sustainable building insulation and biodegradable packaging. EU regulatory shifts—especially Novel Food approvals for CBD—further enable consumer-facing products. Companies such as Hempro International and new-era ventures targeting hemp-based construction materials and plant-based supplements illustrate the growing breadth of the market. Investment Opportunities and Strategic Challenges Europe is increasingly attractive to North American capital. SYNBIOTIC SE exemplifies a diversified strategy, combining medical cannabis and hemp under a unified corporate model. The publicly traded holding company expects revenues to climb from €26 million in 2025 to €47 million by 2027, with positive EBITDA forecasted in 2026. This dual exposure provides a hedge against regulatory divergence and price compression in either sector. David Hyde, founder and CEO of Hyde Advisory & Investments, plays a pivotal role in monitoring and facilitating cannabis investments in Germany. Through his firm's expert brokerage services, Hyde navigates complex regulatory frameworks, matches strategic partners, and helps investors identify high-quality medical cannabis assets in the German market. Drawing from his firm's insights, Hyde notes: Germany's medical cannabis market continues to grow, albeit more slowly than Australia's. While German market competition is increasing, there is lots of room for new brand/category entrants with proper market research, understanding of developed cannabis markets and the right distribution partner(s)." Several industry leaders are confident that Europe represents the next major frontier for cannabis investment. As Boris Jordan, Executive Chairman of Curaleaf, put it, '[Europe is the next big market for cannabis after the U.S.]' Meanwhile, Irwin Simon, CEO of Tilray, emphasizes the scale of the opportunity: 'Germany's de-scheduling of cannabis opens the path to new opportunities in a potential $3 billion medical market; the European Union medical cannabis market is now projected to become $45 billion.' Constantin von der Groeben, founder of Demecan, reflects on Germany's growth momentum: 'The market is on a constant growth that is overwhelming,' while Beau Whitney, head economist at Whitney Economics, sees a broader European transformation underway: 'We can expect an accelerated expansion in the EU of legalised cannabis… If countries reform quickly, then the EU could supplant the U.S. as the major leader in global cannabis reform.' Yet investors must navigate risks: regulatory uncertainty (especially around telemedicine and CBD policy), intense price competition as production scales, limited banking integration, and macroeconomic volatility. The fragmented legal landscape further complicates capital deployment in cannabis-related ventures. Why Legalization Is Working The legalization model in Europe—and particularly in Germany—has shown measurable success. Its framework promotes transparency, standards for safety and quality, and integration into conventional health systems. The emphasis on licensing, standardized extracts, and court-regulated pharmacies mirrors a methodical approach, providing market certainty for investors and patients alike. Moreover, reform frameworks that prioritize illicit-market conversion—such as transitioning traditional, unregulated growers into legal cooperatives—mirror best practices championed by analysts like Whitney Economics. This conversion aligns economic incentives, reduces social harms, and demonstrates the sustainability of the legal regime. Outlook to 2030 As of 2025, both medical cannabis and industrial hemp are poised to become multibillion-euro pillars of Europe's economy. By 2030, medical cannabis in Europe could exceed €10 billion, while industrial hemp ascends as an eco-driven mainstay. Companies rooted in innovation, regulatory compliance, and product diversification will lead market consolidation. Germany will remain the driving force behind this evolution—acting as the regulatory pioneer and investment hub for cannabis in Europe. Institutional and private investors seeking long-term value should consider pan-European platforms that bridge both cannabis segments, such as publicly traded SYNBIOTIC SE. Their IFRS-audited integrated model reflects the shift to a new chapter in medicine and an innovative sustainable economy. END NOTES: CanG Gesetz 2024 – UNCTAD 2022 – Cannabissciencetech 2024 – CannaMonitor 2025 – Credence Research – Grand View Research – IMARC Group – Luminorecruit 2025 – MJBizDaily 2024 – Novel Food – OrganiGram/Sanity Group 2024 – Research And Markets 2024 – Reuters 2024 – Statista – Weedman 2025 –
